Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03760146 · ClinicalTrials.gov registry record · Phase 3
Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,902
- Enrollment target
NCT03760146: Completed Phase 3 study, sponsored by Pfizer.
NCT03760146 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 3,902 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (405% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03760146, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,902 participants
- Enrollment target
Study Summary
A Phase 3, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults
Primary Outcome
Local reactions were recorded using an electronic diary. Local reactions included redness, swelling and pain at the injection site. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 centimeter (cm). Redness and swelling were graded as mild (greater than \[\>\] 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm) and severe (\>10.0 cm). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), and
Interventions
- OTHER Saline
- BIOLOGICAL 13vPnC
- BIOLOGICAL PPSV23
- BIOLOGICAL 20vPnC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,902 participants |
| Start Date | 2018-12-12 |
| Est. Completion | 2019-12-16 |
| Phase | Phase 3 |
What the finished NCT03760146 record still lists
NCT03760146 is an interventional study that assigns participants to a tested intervention. Its 3,902 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (405% higher).
The record links to 0 conditions, and to 4 interventions - of which Saline is the first listed.
NCT03760146 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03760146 about?
NCT03760146 is a clinical study titled "Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults". A Phase 3, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults
What is the current status of trial NCT03760146?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,902 participants. The study started on 2018-12-12. Estimated completion is 2019-12-16.
What interventions are being tested in trial NCT03760146?
The interventions under investigation include: Saline (OTHER), 13vPnC (BIOLOGICAL), PPSV23 (BIOLOGICAL), 20vPnC (BIOLOGICAL).
Who is sponsoring clinical trial NCT03760146?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03760146's enrollment target sits among peer trials
3,902 65th of 2000 higher than 1,936 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05919342 · 3,904 participants · NA
Screening for earlY Heart Failure Diagnosis and Management in Primary Care or at HOme Using Natriuretic Peptides and echocardiographY "SYMPHONY-HF"
- NCT03936335 · 3,930 participants
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
- NCT07087613 · 3,850 participants
Deep Learning Detection of Pulmonary Hypertension and Low Ejection Fraction Via Digital Stethoscope and 3-Lead ECG
- NCT05879926 · 3,960 participants · Phase 3
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI